Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only Articles| Volume 141, ISSUE 2, SUPPLEMENT , e419S-e496S, February 01, 2012

Antithrombotic Therapy for VTE Disease

Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

      Background

      This article addresses the treatment of VTE disease.

      Methods

      We generated strong (Grade 1) and weak (Grade 2) recommendations based on high-quality (Grade A), moderate-quality (Grade B), and low-quality (Grade C) evidence.

      Results

      For acute DVT or pulmonary embolism (PE), we recommend initial parenteral anticoagulant therapy (Grade 1B) or anticoagulation with rivaroxaban. We suggest low-molecular-weight heparin (LMWH) or fondaparinux over IV unfractionated heparin (Grade 2C) or subcutaneous unfractionated heparin (Grade 2B). We suggest thrombolytic therapy for PE with hypotension (Grade 2C). For proximal DVT or PE, we recommend treatment of 3 months over shorter periods (Grade 1B). For a first proximal DVT or PE that is provoked by surgery or by a nonsurgical transient risk factor, we recommend 3 months of therapy (Grade 1B; Grade 2B if provoked by a nonsurgical risk factor and low or moderate bleeding risk); that is unprovoked, we suggest extended therapy if bleeding risk is low or moderate (Grade 2B) and recommend 3 months of therapy if bleeding risk is high (Grade 1B); and that is associated with active cancer, we recommend extended therapy (Grade 1B; Grade 2B if high bleeding risk) and suggest LMWH over vitamin K antagonists (Grade 2B). We suggest vitamin K antagonists or LMWH over dabigatran or rivaroxaban (Grade 2B). We suggest compression stockings to prevent the postthrombotic syndrome (Grade 2B). For extensive superficial vein thrombosis, we suggest prophylactic-dose fondaparinux or LMWH over no anticoagulation (Grade 2B), and suggest fondaparinux over LMWH (Grade 2C).

      Conclusion

      Strong recommendations apply to most patients, whereas weak recommendations are sensitive to differences among patients, including their preferences.

      References

        • Garcia DA
        • Baglin TP
        • Weitz JI
        • Samama MM
        Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e24S-e43S
        • Ageno W
        • Gallus AS
        • Wittkowsky A
        • Crowther M
        • Hylek EM
        • Palareti G
        Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e44S-e88S
        • Holbrook A
        • Schulman S
        • Witt DM
        • et al.
        Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e152S-e184S
        • Bates SM
        • Greer IA
        • Middeldorp S
        • Veenstra DL
        • Prabulos A-M
        • Vandvik PO
        VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e691S-e736S
        • Monagle P
        • Chan AKC
        • Goldenberg NA
        • et al.
        Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e737S-e801S
        • Kearon C
        • Kahn SR
        • Agnelli G
        • Goldhaber S
        • Raskob GE
        • Comerota AJ
        • American College of Chest Physicians
        Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition).
        Chest. 2008; 133: 454S-545S
        • Kearon C.
        Natural history of venous thromboembolism.
        Circulation. 2003; 107: I-22-I30
        • Stein PD
        • Matta F
        • Musani MH
        • Diaczok B
        Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review.
        Am J Med. 2010; 123: 426-431
        • Murin S
        • Romano PS
        • White RH
        Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism.
        Thromb Haemost. 2002; 88: 407-414
        • Baglin T
        • Douketis J
        • Tosetto A
        • et al.
        Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis.
        J Thromb Haemost. 2010; 8: 2436-2442
        • Douketis JD
        • Kearon C
        • Bates S
        • Duku EK
        • Ginsberg JS
        Risk of fatal pulmonary embolism in patients with treated venous thromboembolism.
        JAMA. 1998; 279: 458-462
        • Carrier M
        • Le Gal G
        • Wells PS
        • Rodger MA
        Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism.
        Ann Intern Med. 2010; 152: 578-589
        • Linkins L
        • O'Donnell M
        • Julian JA
        • Kearon C
        Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy.
        J Thromb Haemost. 2010; 8: 2201-2207
        • Linkins LA
        • Choi PT
        • Douketis JD
        Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.
        Ann Intern Med. 2003; 139: 893-900
        • MacLean S
        • Mulla S
        • Akl EA
        • et al.
        Patient values and preferences for decision making in antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e1S-e23S
        • Guyatt GH
        • Norris SL
        • Schulman S
        • et al.
        Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: 53S-70S
        • van der Meer FJ
        • Rosendaal FR
        • Vandenbroucke JP
        • Briët E
        Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.
        Arch Intern Med. 1993; 153: 1557-1562
        • Beyth RJ
        • Quinn LM
        • Landefeld CS
        Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.
        Am J Med. 1998; 105: 91-99
        • Douketis JD
        • Arneklev K
        • Goldhaber SZ
        • Spandorfer J
        • Halperin F
        • Horrow J
        Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
        Arch Intern Med. 2006; 166: 853-859
        • Kuijer PMM
        • Hutten BA
        • Prins MH
        • Büller HR
        Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism.
        Arch Intern Med. 1999; 159: 457-460
        • Landefeld CS
        • McGuire III, E
        • Rosenblatt MW
        A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy.
        Am J Med. 1990; 89: 569-578
        • Palareti G
        • Leali N
        • Coccheri S
        • Italian Study on Complications of Oral Anticoagulant Therapy
        • et al.
        Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT).
        Lancet. 1996; 348: 423-428
        • Torn M
        • Bollen WL
        • van der Meer FJ
        • van der Wall EE
        • Rosendaal FR
        Risks of oral anticoagulant therapy with increasing age.
        Arch Intern Med. 2005; 165: 1527-1532
        • White RH
        • Beyth RJ
        • Zhou H
        • Romano PS
        Major bleeding after hospitalization for deep-venous thrombosis.
        Am J Med. 1999; 107: 414-424
        • Olesen JB
        • Lip GY
        • Hansen PR
        • et al.
        Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort.
        J Thromb Haemost. 2011; 9: 1460-1467
        • Fihn SD
        • Callahan CM
        • Martin DC
        • McDonell MB
        • Henikoff JG
        • White RH
        • The National Consortium of Anticoagulation Clinics
        The risk for and severity of bleeding complications in elderly patients treated with warfarin.
        Ann Intern Med. 1996; 124: 970-979
        • Gage BF
        • Yan Y
        • Milligan PE
        • et al.
        Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).
        Am Heart J. 2006; 151: 713-719
        • Lip GY
        • Frison L
        • Halperin JL
        • Lane DA
        Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
        J Am Coll Cardiol. 2011; 57: 173-180
        • Nieto JA
        • Bruscas MJ
        • Ruiz-Ribo D
        • RIETE Investigators
        • et al.
        Acute venous thromboembolism in patients with recent major bleeding. The influence of the site of bleeding and the time elapsed on outcome.
        J Thromb Haemost. 2006; 4: 2367-2372
        • Ruíz-Giménez N
        • Suárez C
        • González R
        • RIETE Investigators
        • et al.
        Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry.
        Thromb Haemost. 2008; 100: 26-31
        • van der Meer FJ
        • Rosendaal FR
        • Vandenbroucke JP
        • Briët E
        Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants.
        Thromb Haemost. 1996; 76: 12-16
        • Pengo V
        • Legnani C
        • Noventa F
        • Palareti G
        • ISCOAT Study Group
        • (Italian Study on Complications of Oral Anticoagulant Therapy)
        Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study.
        Thromb Haemost. 2001; 85: 418-422
        • Fang MC
        • Go AS
        • Chang Y
        • et al.
        A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.
        J Am Coll Cardiol. 2011; 58: 395-401
        • Shireman TI
        • Mahnken JD
        • Howard PA
        • Kresowik TF
        • Hou Q
        • Ellerbeck EF
        Development of a contemporary bleeding risk model for elderly warfarin recipients.
        Chest. 2006; 130: 1390-1396
        • Fihn SD
        • McDonell M
        • Martin D
        • Warfarin Optimized Outpatient Follow-up Study Group
        • et al.
        Risk factors for complications of chronic anticoagulation. A multicenter study.
        Ann Intern Med. 1993; 118: 511-520
        • Nieto JA
        • Solano R
        • Ruiz-Ribó MD
        • Riete Investigators
        • et al.
        Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry.
        J Thromb Haemost. 2010; 8: 1216-1222
        • Hutten BA
        • Prins MH
        • Gent M
        • Ginsberg J
        • Tijssen JG
        • Büller HR
        Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.
        J Clin Oncol. 2000; 18: 3078-3083
        • Prandoni P
        • Lensing AW
        • Piccioli A
        • et al.
        Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
        Blood. 2002; 100: 3484-3488
        • Hylek EM
        • Singer DE
        Risk factors for intracranial hemorrhage in outpatients taking warfarin.
        Ann Intern Med. 1994; 120: 897-902
        • Dentali F
        • Ageno W
        • Becattini C
        • et al.
        Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis.
        Thromb Res. 2010; 125: 518-522
        • Hull RD
        • Raskob GE
        • Rosenbloom D
        • et al.
        Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.
        N Engl J Med. 1990; 322: 1260-1264
        • Dahri K
        • Loewen P
        The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules.
        Thromb Haemost. 2007; 98: 980-987
        • Palareti G
        • Cosmi B
        Bleeding with anticoagulation therapy-who is at risk, and how best to identify such patients.
        Thromb Haemost. 2009; 102: 268-278
        • Kearon C
        • Ginsberg JS
        • Kovacs MJ
        • Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators
        • et al.
        Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.
        N Engl J Med. 2003; 349: 631-639
        • Collins R
        • MacMahon S
        • Flather M
        • et al.
        Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.
        BMJ. 1996; 313: 652-659
        • Yusuf S
        • Mehta SR
        • Xie C
        • CREATE Trial Group Investigators
        • et al.
        Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.
        JAMA. 2005; 293: 427-435
        • Prandoni P
        • Lensing AWA
        • Cogo A
        • et al.
        The long-term clinical course of acute deep venous thrombosis.
        Ann Intern Med. 1996; 125: 1-7
        • Palareti G
        • Cosmi B
        • Legnani C
        • PROLONG Investigators
        • et al.
        D-dimer testing to determine the duration of anticoagulation therapy.
        N Engl J Med. 2006; 355: 1780-1789
        • Wells PS
        • Forgie MA
        • Simms M
        • et al.
        The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism.
        Arch Intern Med. 2003; 163: 917-920
        • Barritt DW
        • Jordan SC
        Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.
        Lancet. 1960; 1: 1309-1312
        • Brandjes DPM
        • Heijboer H
        • Büller HR
        • de Rijk M
        • Jagt H
        • ten Cate JW
        Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.
        N Engl J Med. 1992; 327: 1485-1489
        • Hull RD
        • Raskob GE
        • Hirsh J
        • et al.
        Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.
        N Engl J Med. 1986; 315: 1109-1114
        • Raschke RA
        • Reilly BM
        • Guidry JR
        • Fontana JR
        • Srinivas S
        The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial.
        Ann Intern Med. 1993; 119: 874-881
        • Wells PS
        • Hirsh J
        • Anderson DR
        • et al.
        A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process.
        J Intern Med. 1998; 243: 15-23
        • Le Gal G
        • Righini M
        • Roy PM
        • et al.
        Prediction of pulmonary embolism in the emergency department: the revised Geneva score.
        Ann Intern Med. 2006; 144: 165-171
        • Wells PS
        • Anderson DR
        • Rodger M
        • et al.
        Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer.
        Thromb Haemost. 2000; 83: 416-420
        • Bates SM
        • Jaeschke R
        • Stevens SM
        • et al.
        Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e351S-e418S
        • Johnson SA
        • Stevens SM
        • Woller SC
        • et al.
        Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis.
        JAMA. 2010; 303: 438-445
        • Bernardi E
        • Camporese G
        • Büller HR
        • Erasmus Study Group
        • et al.
        Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial.
        JAMA. 2008; 300: 1653-1659
        • Masuda EM
        • Kistner RL
        The case for managing calf vein thrombi with duplex surveillance and selective anticoagulation.
        Dis Mon. 2010; 56: 601-613
        • Palareti G
        • Cosmi B
        • Lessiani G
        • et al.
        Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study.
        Thromb Haemost. 2010; 104: 1063-1070
        • Righini M
        • Paris S
        • Le Gal G
        • Laroche JP
        • Perrier A
        • Bounameaux H
        Clinical relevance of distal deep vein thrombosis. Review of literature data.
        Thromb Haemost. 2006; 95: 56-64
        • Macdonald PS
        • Kahn SR
        • Miller N
        • Obrand D
        Short-term natural history of isolated gastrocnemius and soleal vein thrombosis.
        J Vasc Surg. 2003; 37: 523-527
        • Parisi R
        • Visonà A
        • Camporese G
        • et al.
        Isolated distal deep vein thrombosis: efficacy and safety of a protocol of treatment. Treatment of Isolated Calf Thrombosis (TICT) Study.
        Int Angiol. 2009; 28: 68-72
        • Schwarz T
        • Buschmann L
        • Beyer J
        • Halbritter K
        • Rastan A
        • Schellong S
        Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study.
        J Vasc Surg. 2010; 52: 1246-1250
        • Lagerstedt CI
        • Olsson CG
        • Fagher BO
        • Oqvist BW
        • Albrechtsson U
        Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis.
        Lancet. 1985; 2: 515-518
        • Gallus AS
        • Jackaman J
        • Tillett J
        • Mills W
        • Wycherley A
        Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.
        Lancet. 1986; 2: 1293-1296
        • Leroyer C
        • Bressollette L
        • Oger E
        • The ANTENOX Study Group
        • et al.
        Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. a randomized clinical trial.
        Haemostasis. 1998; 28: 70-77
        • Linkins L-A
        • Dans AL
        • Moores LK
        • et al.
        Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e495S-e530S
        • Prandoni P
        • Carnovali M
        • Marchiori A
        • Galilei Investigators
        Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
        Arch Intern Med. 2004; 164: 1077-1083
        • Kearon C
        • Ginsberg JS
        • Julian JA
        • Fixed-Dose Heparin (FIDO) Investigators
        • et al.
        Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
        JAMA. 2006; 296: 935-942
        • Dolovich LR
        • Ginsberg JS
        • Douketis JD
        • Holbrook AM
        • Cheah G
        A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.
        Arch Intern Med. 2000; 160: 181-188
        • Gould MK
        • Dembitzer AD
        • Doyle RL
        • Hastie TJ
        • Garber AM
        Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.
        Ann Intern Med. 1999; 130: 800-809
        • van Dongen CJJ
        • van den Belt AG
        • Prins MH
        Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
        Cochrane Database Syst Rev. 2004; : CD001100
        • Erkens PM
        • Prins MH
        Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
        Cochrane Database Syst Rev. 2010; : CD001100
        • Faivre R
        • Neuhart Y
        • Kieffer Y
        • et al.
        [A new treatment of deep venous thrombosis: low molecular weight heparin fractions. Randomized study].
        Presse Med. 1988; 17: 197-200
        • Lopaciuk S
        • Meissner AJ
        • Filipecki S
        • et al.
        Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
        Thromb Haemost. 1992; 68: 14-18
        • Büller HR
        • Davidson BL
        • Decousus H
        • Matisse Investigators
        • et al.
        Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
        Ann Intern Med. 2004; 140: 867-873
        • Büller HR
        • Davidson BL
        • Decousus H
        • Matisse Investigators
        • et al.
        Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
        N Engl J Med. 2003; 349: 1695-1702
        • Couturaud F
        • Julian JA
        • Kearon C
        Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
        Thromb Haemost. 2001; 86: 980-984
        • van Dongen CJ
        • MacGillavry MR
        • Prins MH
        Once versus twice daily LMWH for the initial treatment of venous thromboembolism.
        Cochrane Database Syst Rev. 2005; : CD003074
        • Breddin HK
        • Hach-Wunderle V
        • Nakov R
        • Kakkar VV
        • CORTES Investigators
        • Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety
        Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
        N Engl J Med. 2001; 344: 626-631
        • Charbonnier BA
        • Fiessinger JN
        • Banga JD
        • Wenzel E
        • d'Azemar P
        • Sagnard L
        Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
        Thromb Haemost. 1998; 79: 897-901
        • Holmoström M
        • Berglund MC
        • Granquist S
        • Bratt G
        • Törnebohm E
        • Lockner D
        Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg.
        Thromb Res. 1992; 67: 49-55
        • Merli G
        • Spiro TE
        • Olsson CG
        • Enoxaparin Clinical Trial Group
        • et al.
        Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
        Ann Intern Med. 2001; 134: 191-202
        • Partsch H
        • Kechavarz B
        • Mostbeck A
        • Köhn H
        • Lipp C
        Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin.
        J Vasc Surg. 1996; 24: 774-782
        • Siegbahn A
        • Y-Hassan S
        • Boberg J
        • et al.
        Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo.
        Thromb Res. 1989; 55: 767-778
        • Bauersachs R
        • Berkowitz SD
        • Brenner B
        • EINSTEIN Investigators
        • et al.
        Oral rivaroxaban for symptomatic venous thromboembolism.
        N Engl J Med. 2010; 363: 2499-2510
        • Boccalon H
        • Elias A
        • Chalé JJ
        • Cadène A
        • Gabriel S
        Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study.
        Arch Intern Med. 2000; 160: 1769-1773
        • Chong BH
        • Brighton TA
        • Baker RI
        • Thurlow P
        • Lee CH
        • ASTH DVT Study Group
        Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.
        J Thromb Thrombolysis. 2005; 19: 173-181
        • Daskalopoulos ME
        • Daskalopoulou SS
        • Tzortzis E
        • et al.
        Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial.
        Eur J Vasc Endovasc Surg. 2005; 29: 638-650
        • Koopman MMW
        • Prandoni P
        • Piovella F
        • The Tasman Study Group
        • et al.
        Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home.
        N Engl J Med. 1996; 334: 682-687
        • Levine M
        • Gent M
        • Hirsh J
        • et al.
        A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
        N Engl J Med. 1996; 334: 677-681
        • Ramacciotti E
        • Araújo GR
        • Lastoria S
        • CLETRAT Investigators
        • et al.
        An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
        Thromb Res. 2004; 114: 149-153
        • Bäckman K
        • Carlsson P
        • Kentson M
        • Hansen S
        • Engquist L
        • Hallert C
        Deep venous thrombosis: a new task for primary health care. A randomised economic study of outpatient and inpatient treatment.
        Scand J Prim Health Care. 2004; 22: 44-49
        • O'Brien B
        • Levine M
        • Willan A
        • et al.
        Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis.
        Arch Intern Med. 1999; 159: 2298-2304
        • Huse DM
        • Cummins G
        • Taylor DC
        • Russell MW
        Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
        Am J Manag Care. 2002; 8: S10-S16
        • Spyropoulos AC
        • Hurley JS
        • Ciesla GN
        • de Lissovoy G
        Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin.
        Chest. 2002; 122: 108-114
        • Tillman DJ
        • Charland SL
        • Witt DM
        Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization.
        Arch Intern Med. 2000; 160: 2926-2932
        • Rodger M
        • Bredeson C
        • Wells PS
        • Beck J
        • Kearns B
        • Huebsch LB
        Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
        CMAJ. 1998; 159: 931-938
        • van den Belt AG
        • Bossuyt PM
        • Prins MH
        • Gallus AS
        • Büller HR
        • TASMAN Study Group
        Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis—an economic evaluation.
        Thromb Haemost. 1998; 79: 259-263
        • Kahn SR
        • Shrier I
        • Julian JA
        • et al.
        Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis.
        Ann Intern Med. 2008; 149: 698-707
        • Sharifi M
        • Mehdipour M
        • Bay C
        • Smith G
        • Sharifi J
        Endovenous therapy for deep venous thrombosis: the TORPEDO trial.
        Catheter Cardiovasc Interv. 2010; 76: 316-325
        • Jaff MR
        • McMurtry MS
        • Archer SL
        • et al.
        American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriocsclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.
        Circulation. 2011; 123: 1788-1830
        • Elsharawy M
        • Elzayat E
        Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial.
        Eur J Vasc Endovasc Surg. 2002; 24: 209-214
        • Enden T
        • Kløw NE
        • Sandvik L
        • CaVenT study group
        • et al.
        Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency.
        J Thromb Haemost. 2009; 7: 1268-1275
        • Enden T
        • Sandvik L
        • Kløw NE
        • et al.
        Catheter-directed venous thrombolysis in acute iliofemoral vein thrombosis—the CaVenT study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771).
        Am Heart J. 2007; 154: 808-814
        • Douketis JD
        • Foster GA
        • Crowther MA
        • Prins MH
        • Ginsberg JS
        Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.
        Arch Intern Med. 2000; 160: 3431-3436
        • Comerota AJ
        • Throm RC
        • Mathias SD
        • Haughton S
        • Mewissen M
        Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life.
        J Vasc Surg. 2000; 32: 130-137
        • Brass LM
        • Lichtman JH
        • Wang Y
        • Gurwitz JH
        • Radford MJ
        • Krumholz HM
        Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project.
        Stroke. 2000; 31: 1802-1811
        • Mehta RH
        • Stebbins A
        • Lopes RD
        • et al.
        Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy.
        Am J Med. 2011; 124: 48-57
      1. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.
        Lancet. 1994; 343: 311-322
        • Piazza G
        • Goldhaber SZ
        Fibrinolysis for acute pulmonary embolism.
        Vasc Med. 2010; 15: 419-428
        • Todd JL
        • Tapson VF
        Thrombolytic therapy for acute pulmonary embolism: a critical appraisal.
        Chest. 2009; 135: 1321-1329
        • Kasirajan K
        • Gray B
        • Ouriel K
        Percutaneous AngioJet thrombectomy in the management of extensive deep venous thrombosis.
        J Vasc Interv Radiol. 2001; 12: 179-185
        • Vedantham S
        • Vesely TM
        • Parti N
        • Darcy M
        • Hovsepian DM
        • Picus D
        Lower extremity venous thrombolysis with adjunctive mechanical thrombectomy.
        J Vasc Interv Radiol. 2002; 13: 1001-1008
        • Delomez M
        • Beregi JP
        • Willoteaux S
        • et al.
        Mechanical thrombectomy in patients with deep venous thrombosis.
        Cardiovasc Intervent Radiol. 2001; 24: 42-48
        • Kinney TB
        • Valji K
        • Rose SC
        • et al.
        Pulmonary embolism from pulse-spray pharmacomechanical thrombolysis of clotted hemodialysis grafts: urokinase versus heparinized saline.
        J Vasc Interv Radiol. 2000; 11: 1143-1152
        • Arnesen H
        • Heilo A
        • Jakobsen E
        • Ly B
        • Skaga E
        A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis.
        Acta Med Scand. 1978; 203: 457-463
        • Arnesen H
        • Høiseth A
        • Ly B
        Streptokinase of heparin in the treatment of deep vein thrombosis. Follow-up results of a prospective study.
        Acta Med Scand. 1982; 211: 65-68
        • Browse NL
        • Thomas ML
        • Pim HP
        Streptokinase and deep vein thrombosis.
        BMJ. 1968; 3: 717-720
        • Duckert F
        • Müller G
        • Nyman D
        • et al.
        Treatment of deep vein thrombosis with streptokinase.
        BMJ. 1975; 1: 479-481
        • Elliot MS
        • Immelman EJ
        • Jeffery P
        • et al.
        A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial.
        Br J Surg. 1979; 66: 838-843
        • Goldhaber SZ
        • Meyerovitz MF
        • Green D
        • et al.
        Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis.
        Am J Med. 1990; 88: 235-240
        • Kakkar VV
        • Flanc C
        • Howe CT
        • O'Shea M
        • Flute PT
        Treatment of deep vein thrombosis. A trial of heparin, streptokinase, and arvin.
        BMJ. 1969; 1: 806-810
        • Kiil J
        • Carvalho A
        • Saksø P
        • Nielsen HO
        Urokinase or heparin in the management of patients with deep vein thrombosis?.
        Acta Chir Scand. 1981; 147: 529-532
        • Laiho MK
        • Oinonen A
        • Sugano N
        • et al.
        Preservation of venous valve function after catheter-directed and systemic thrombolysis for deep venous thrombosis.
        Eur J Vasc Endovasc Surg. 2004; 28: 391-396
        • Marder VJ
        • Soulen RL
        • Atichartakarn V
        • et al.
        Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy.
        J Lab Clin Med. 1977; 89: 1018-1029
        • Porter JM
        • Seaman AJ
        • Common HH
        • Rösch J
        • Eidemiller LR
        • Calhoun AD
        Comparison of heparin and streptokinase in the treatment of venous thrombosis.
        Am Surg. 1975; 41: 511-519
        • Robertson BR
        • Nilsson IM
        • Nylander G
        Value of streptokinase and heparin in treatment of acute deep venous thrombosis. A coded investigation.
        Acta Chir Scand. 1968; 134: 203-208
        • Schulman S
        • Granqvist S
        • Juhlin-Dannfelt A
        • Lockner D
        Long-term sequelae of calf vein thrombosis treated with heparin or low-dose streptokinase.
        Acta Med Scand. 1986; 219: 349-357
        • Schweizer J
        • Elix H
        • Altmann E
        • Hellner G
        • Forkmann L
        Comparative results of thrombolysis treatment with rt-PA and urokinase: a pilot study.
        Vasa. 1998; 27: 167-171
        • Schweizer J
        • Kirch W
        • Koch R
        • et al.
        Short- and long-term results after thrombolytic treatment of deep venous thrombosis.
        J Am Coll Cardiol. 2000; 36: 1336-1343
        • Tsapogas MJ
        • Peabody RA
        • Wu KT
        • Karmody AM
        • Devaraj KT
        • Eckert C
        Controlled study of thrombolytic therapy in deep vein thrombosis.
        Surgery. 1973; 74: 973-984
        • Turpie AG
        • Levine MN
        • Hirsh J
        • et al.
        Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial.
        Chest. 1990; 97: 172S-175S
        • Verhaeghe R
        • Besse P
        • Bounameaux H
        • Marbet GA
        Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/or pelvis.
        Thromb Res. 1989; 55: 5-11
        • Watz R
        • Savidge GF
        Rapid thrombolysis and preservation of valvular venous function in high deep vein thrombosis. A comparative study between streptokinase and heparin therapy.
        Acta Med Scand. 1979; 205: 293-298
        • Watson LI
        • Armon MP
        Thrombolysis for acute deep vein thrombosis.
        Cochrane Database Syst Rev. 2004; : CD002783
        • Common HH
        • Seaman AJ
        • Rösch J
        • Porter JM
        • Dotter CT
        Deep vein thrombosis treated with streptokinase or heparin. Follow-up of a randomized study.
        Angiology. 1976; 27: 645-654
        • Comerota AJ
        • Gale SS
        Technique of contemporary iliofemoral and infrainguinal venous thrombectomy.
        J Vasc Surg. 2006; 43: 185-191
        • Karp RB
        • Wylie EJ
        Recurrent thrombosis after iliofemoral venous thrombectomy.
        Surg Forum. 1966; 17: 147
        • Lansing AM
        • Davis WM
        Five-year follow-up study of iliofemoral venous thrombectomy.
        Ann Surg. 1968; 168: 620-628
        • Plate G
        • Akesson H
        • Einarsson E
        • Ohlin P
        • Eklöf B
        Long-term results of venous thrombectomy combined with a temporary arterio-venous fistula.
        Eur J Vasc Surg. 1990; 4: 483-489
        • Plate G
        • Einarsson E
        • Ohlin P
        • Jensen R
        • Qvarfordt P
        • Eklöf B
        Thrombectomy with temporary arteriovenous fistula: the treatment of choice in acute iliofemoral venous thrombosis.
        J Vasc Surg. 1984; 1: 867-876
        • Plate G
        • Eklöf B
        • Norgren L
        • Ohlin P
        • Dahlström JA
        Venous thrombectomy for iliofemoral vein thrombosis—10-year results of a prospective randomised study.
        Eur J Vasc Endovasc Surg. 1997; 14: 367-374
        • Decousus H
        • Leizorovicz A
        • Parent F
        • et al.
        A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
        N Engl J Med. 1998; 338: 409-415
        • Mismetti P
        • Rivron-Guillot K
        • Quenet S
        • et al.
        A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism.
        Chest. 2007; 131: 223-229
        • Athanasoulis CA
        • Kaufman JA
        • Halpern EF
        • Waltman AC
        • Geller SC
        • Fan CM
        Inferior vena caval filters: review of a 26-year single-center clinical experience.
        Radiology. 2000; 216: 54-66
        • Cosmi B
        • Legnani C
        • Cini M
        • Guazzaloca G
        • Palareti G
        D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis.
        Thromb Haemost. 2005; 94: 969-974
        • Streiff MB
        Vena caval filters: a comprehensive review.
        Blood. 2000; 95: 3669-3677
        • Hajduk B
        • Tomkowski WZ
        • Malek G
        • Davidson BL
        Vena cava filter occlusion and venous thromboembolism risk in persistently anticoagulated patients: a prospective, observational cohort study.
        Chest. 2010; 137: 877-882
        • Fox MA
        • Kahn SR
        Postthrombotic syndrome in relation to vena cava filter placement: a systematic review.
        J Vasc Interv Radiol. 2008; 19: 981-985
        • Usoh F
        • Hingorani A
        • Ascher E
        • et al.
        Prospective randomized study comparing the clinical outcomes between inferior vena cava Greenfield and TrapEase filters.
        J Vasc Surg. 2010; 52: 394-399
        • Nicholson W
        • Nicholson WJ
        • Tolerico P
        • et al.
        Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade.
        Arch Intern Med. 2010; 170: 1827-1831
        • Dabbagh O
        • Nagam N
        • Chitima-Matsiga R
        • Bearelly S
        • Bearelly D
        Retrievable inferior vena cava filters are not getting retrieved: where is the gap?.
        Thromb Res. 2010; 126: 493-497
        • Aissaoui N
        • Martins E
        • Mouly S
        • Weber S
        • Meune C
        A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both.
        Int J Cardiol. 2009; 137: 37-41
        • Kahn SR
        • Shrier I
        • Kearon C
        Physical activity in patients with deep venous thrombosis: a systematic review.
        Thromb Res. 2008; 122: 763-773
        • Hull R
        • Delmore T
        • Genton E
        • et al.
        Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.
        N Engl J Med. 1979; 301: 855-858
        • Levine MN
        • Hirsh J
        • Gent M
        • et al.
        Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.
        Thromb Haemost. 1995; 74: 606-611
        • Research Committee of the British Thoracic Society
        Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism.
        Lancet. 1992; 340: 873-876
        • Schulman S
        • Granqvist S
        • Holmström M
        • The Duration of Anticoagulation Trial Study Group
        • et al.
        The duration of oral anticoagulant therapy after a second episode of venous thromboembolism.
        N Engl J Med. 1997; 336: 393-398
        • Baglin T
        • Luddington R
        • Brown K
        • Baglin C
        Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.
        Lancet. 2003; 362: 523-526
        • Christiansen SC
        • Cannegieter SC
        • Koster T
        • Vandenbroucke JP
        • Rosendaal FR
        Thrombophilia, clinical factors, and recurrent venous thrombotic events.
        JAMA. 2005; 293: 2352-2361
        • Hansson PO
        • Sörbo J
        • Eriksson H
        Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors.
        Arch Intern Med. 2000; 160: 769-774
        • Heit JA
        • Mohr DN
        • Silverstein MD
        • Petterson TM
        • O'Fallon WM
        • Melton III, LJ
        Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.
        Arch Intern Med. 2000; 160: 761-768
        • Palareti G
        • Legnani C
        • Cosmi B
        • Guazzaloca G
        • Pancani C
        • Coccheri S
        Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.
        Thromb Haemost. 2002; 87: 7-12
        • Pinede L
        • Ninet J
        • Duhaut P
        • Investigators of the “Durée Optimale du Traitement AntiVitamines K” (DOTAVK) Study
        • et al.
        Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis.
        Circulation. 2001; 103: 2453-2460
        • Pini M
        • Aiello S
        • Manotti C
        • et al.
        Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis.
        Thromb Haemost. 1994; 72: 191-197
        • Schulman S
        • Rhedin AS
        • Lindmarker P
        • Duration of Anticoagulation Trial Study Group
        • et al.
        A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism.
        N Engl J Med. 1995; 332: 1661-1665
        • Boutitie F
        • Pinede L
        • Schulman S
        • et al.
        Influence of preceding duration of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping therapy: analysis of individual participants' data from seven trials.
        BMJ. 2011; 342: d3036
        • Iorio A
        • Kearon C
        • Filippucci E
        • et al.
        Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review.
        Arch Intern Med. 2010; 170: 1710-1716
        • Palareti G
        • Legnani C
        • Lee A
        • et al.
        A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy.
        Thromb Haemost. 2000; 84: 805-810
        • Lee AY
        • Levine MN
        • Baker RI
        • Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators
        • et al.
        Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
        N Engl J Med. 2003; 349: 146-153
        • Ridker PM
        • Goldhaber SZ
        • Danielson E
        • PREVENT Investigators
        • et al.
        Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
        N Engl J Med. 2003; 348: 1425-1434
        • Schulman S
        • Wåhlander K
        • Lundström T
        • Clason SB
        • Eriksson H
        • THRIVE III Investigators
        Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
        N Engl J Med. 2003; 349: 1713-1721
        • Eichinger S
        • Minar E
        • Bialonczyk C
        • et al.
        D-dimer levels and risk of recurrent venous thromboembolism.
        JAMA. 2003; 290: 1071-1074
        • Palareti G
        • Legnani C
        • Cosmi B
        • et al.
        Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.
        Circulation. 2003; 108: 313-318
        • Shrivastava S
        • Ridker PM
        • Glynn RJ
        • et al.
        D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism.
        J Thromb Haemost. 2006; 4: 1208-1214
        • Cosmi B
        • Legnani C
        • Tosetto A
        • PROLONG Investigators (on behalf of Italian Federation of Anticoagulation Clinics)
        • et al.
        Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study.
        Blood. 2010; 115: 481-488
        • Douketis J
        • Tosetto A
        • Marcucci M
        • et al.
        Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.
        Ann Intern Med. 2010; 153: 523-531
        • Verhovsek M
        • Douketis JD
        • Yi Q
        • et al.
        Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism.
        Ann Intern Med. 2008; 149: 481-490
        • Kearon C
        • Gent M
        • Hirsh J
        • et al.
        A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
        N Engl J Med. 1999; 340: 901-907
        • Schulman S
        • Lindmarker P
        • Holmström M
        • et al.
        Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months.
        J Thromb Haemost. 2006; 4: 734-742
        • Schulman S
        • Svenungsson E
        • Granqvist S
        • Duration of Anticoagulation Study Group
        Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy.
        Am J Med. 1998; 104: 332-338
        • Rodger MA
        • Kahn SR
        • Wells PS
        • et al.
        Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy.
        CMAJ. 2008; 179: 417-426
        • Eichinger S
        • Pabinger I
        • Stümpflen A
        • et al.
        The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
        Thromb Haemost. 1997; 77: 624-628
        • Ho WK
        • Hankey GJ
        • Quinlan DJ
        • Eikelboom JW
        Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.
        Arch Intern Med. 2006; 166: 729-736
        • Lindmarker P
        • Schulman S
        • Sten-Linder M
        • Wiman B
        • Egberg N
        • Johnsson H
        The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation.
        Thromb Haemost. 1999; 81: 684-689
        • Segal JB
        • Brotman DJ
        • Necochea AJ
        • et al.
        Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review.
        JAMA. 2009; 301: 2472-2485
        • Kearon C
        • Julian JA
        • Kovacs MJ
        • ELATE Investigators
        • et al.
        Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.
        Blood. 2008; 112: 4432-4436
        • McRae S
        • Tran H
        • Schulman S
        • Ginsberg J
        • Kearon C
        Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis.
        Lancet. 2006; 368: 371-378
        • Douketis J
        • Tosetto A
        • Marcucci M
        • et al.
        Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis.
        BMJ. 2011; 342: d813
        • White RH
        • Zhou H
        • Romano PS
        Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California.
        Ann Intern Med. 1998; 128: 737-740
        • Agnelli G
        • Prandoni P
        • Becattini C
        • Warfarin Optimal Duration Italian Trial Investigators
        • et al.
        Extended oral anticoagulant therapy after a first episode of pulmonary embolism.
        Ann Intern Med. 2003; 139: 19-25
        • Kearon C
        • Ginsberg JS
        • Anderson DR
        • SOFAST Investigators
        • et al.
        Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor.
        J Thromb Haemost. 2004; 2: 743-749
        • Piovella F
        • Crippa L
        • Barone M
        • et al.
        Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis.
        Haematologica. 2002; 87: 515-522
        • Prandoni P
        • Lensing AW
        • Prins MH
        • et al.
        Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism.
        Ann Intern Med. 2002; 137: 955-960
        • Carrier M
        • Rodger MA
        • Wells PS
        • Righini M
        • LE Gal G
        Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis.
        J Thromb Haemost. 2011; 9: 1119-1125
        • Eichinger S
        • Heinze G
        • Jandeck LM
        • Kyrle PA
        Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model.
        Circulation. 2010; 121: 1630-1636
        • Stain M
        • Schönauer V
        • Minar E
        • et al.
        The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease.
        J Thromb Haemost. 2005; 3: 2671-2676
        • Brandjes DP
        • Büller HR
        • Heijboer H
        • et al.
        Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis.
        Lancet. 1997; 349: 759-762
        • Prandoni P
        • Lensing AW
        • Prins MH
        • et al.
        Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial.
        Ann Intern Med. 2004; 141: 249-256
        • Campbell IA
        • Bentley DP
        • Prescott RJ
        • Routledge PA
        • Shetty HG
        • Williamson IJ
        Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial.
        BMJ. 2007; 334: 674-680
        • Agnelli G
        • Prandoni P
        • Santamaria MG
        • Warfarin Optimal Duration Italian Trial Investigators
        • et al.
        Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis.
        N Engl J Med. 2001; 345: 165-169
        • Siragusa S
        • Malato A
        • Anastasio R
        • et al.
        Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study.
        Blood. 2008; 112: 511-515
        • Prandoni P
        • Prins MH
        • Lensing AW
        • AESOPUS Investigators
        • et al.
        Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial.
        Ann Intern Med. 2009; 150: 577-585
        • Farraj RS
        Anticoagulation period in idiopathic venous thromboembolism. How long is enough?.
        Saudi Med J. 2004; 25: 848-851
        • Prandoni P
        • Noventa F
        • Ghirarduzzi A
        • et al.
        The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
        Haematologica. 2007; 92: 199-205
        • van Dongen CJ
        • Prandoni P
        • Frulla M
        • Marchiori A
        • Prins MH
        • Hutten BA
        Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome.
        J Thromb Haemost. 2005; 3: 939-942
        • Locadia M
        • Bossuyt PM
        • Stalmeier PF
        • et al.
        Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences.
        Thromb Haemost. 2004; 92: 1336-1341
        • Hull RD
        • Pineo GF
        • Brant RF
        • LITE Trial Investigators
        • et al.
        Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms.
        Am J Med. 2007; 120: 72-82
        • Beyth RJ
        • Cohen AM
        • Landefeld CS
        Long-term outcomes of deep-vein thrombosis.
        Arch Intern Med. 1995; 155: 1031-1037
        • Hull RD
        • Pineo GF
        • Brant R
        • et al.
        Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome.
        Am J Med. 2009; 122: 762-769
        • Kahn SR
        • Ginsberg JS
        Relationship between deep venous thrombosis and the postthrombotic syndrome.
        Arch Intern Med. 2004; 164: 17-26
        • Hull R
        • Delmore T
        • Carter C
        • et al.
        Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.
        N Engl J Med. 1982; 306: 189-194
        • Monreal M
        • Lafoz E
        • Olive A
        • del Rio L
        • Vedia C
        Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
        Thromb Haemost. 1994; 71: 7-11
        • Buller HR
        • Cohen AT
        • Davidson B
        • van Gogh Investigators
        • et al.
        Idraparinux versus standard therapy for venous thromboembolic disease.
        N Engl J Med. 2007; 357: 1094-1104
        • Iorio A
        • Guercini F
        • Pini M
        Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.
        J Thromb Haemost. 2003; 1: 1906-1913
        • van der Heijden JF
        • Hutten BA
        • Büller HR
        • et al.
        Prins MH Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
        Cochrane Database Syst Rev. 2002; : CD002001
        • Gonzalez-Fajardo JA
        • Arreba E
        • Castrodeza J
        • et al.
        Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.
        J Vasc Surg. 1999; 30: 283-292
        • Hull R
        • Pineo G
        • Mah A
        • et al.
        Long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis [abstract].
        Blood. 2000; 96: 449a
        • Lopaciuk S
        • Bielska-Falda H
        • Noszczyk W
        • et al.
        Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
        Thromb Haemost. 1999; 81: 26-31
        • López-Beret P
        • Orgaz A
        • Fontcuberta J
        • et al.
        Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis.
        J Vasc Surg. 2001; 33: 77-90
        • Veiga F
        • Escribá A
        • Maluenda MP
        • et al.
        Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
        Thromb Haemost. 2000; 84: 559-564
        • Deitcher SR
        • Kessler CM
        • Merli G
        • Rigas JR
        • Lyons RM
        • Fareed J
        • ONCENOX Investigators
        Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
        Clin Appl Thromb Hemost. 2006; 12: 389-396
        • Meyer G
        • Marjanovic Z
        • Valcke J
        • et al.
        Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
        Arch Intern Med. 2002; 162: 1729-1735
        • Romera A
        • Cairols MA
        • Vila-Coll R
        • et al.
        A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis.
        Eur J Vasc Endovasc Surg. 2009; 37: 349-356
        • Varki A
        Trousseau's syndrome: multiple definitions and multiple mechanisms.
        Blood. 2007; 110: 1723-1729
        • Falck-Ytter Y
        • Francis CW
        • Johanson NA
        • et al.
        Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e278S-e325S
        • Robinson KS
        • Anderson DR
        • Gross M
        • et al.
        Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial.
        Ann Intern Med. 1997; 127: 439-445
        • Kahn SR
        • Ginsberg JS
        The post-thrombotic syndrome: current knowledge, controversies, and directions for future research.
        Blood Rev. 2002; 16: 155-165
        • Ginsberg JS
        • Hirsh J
        • Julian J
        • et al.
        Prevention and treatment of postphlebitic syndrome: results of a 3-part study.
        Arch Intern Med. 2001; 161: 2105-2109
        • Partsch H
        • Kaulich M
        • Mayer W
        Immediate mobilisation in acute vein thrombosis reduces post-thrombotic syndrome.
        Int Angiol. 2004; 23: 206-212
        • Aschwanden M
        • Jeanneret C
        • Koller MT
        • Thalhammer C
        • Bucher HC
        • Jaeger KA
        Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial.
        J Vasc Surg. 2008; 47: 1015-1021
        • Roumen-Klappe EM
        • den Heijer M
        • van Rossum J
        • et al.
        Multilayer compression bandaging in the acute phase of deep-vein thrombosis has no effect on the development of the post-thrombotic syndrome.
        J Thromb Thrombolysis. 2009; 27: 400-405
        • Ten Cate-Hoek AJ
        • Ten Cate H
        • Tordoir J
        • Hamulyák K
        • Prins MH
        Individually tailored duration of elastic compression therapy in relation to incidence of the postthrombotic syndrome.
        J Vasc Surg. 2010; 52: 132-138
        • Frulla M
        • Marchiori A
        • Sartor D
        • et al.
        Elastic stockings, hydroxyethylrutosides or both for the treatment of post-thrombotic syndrome.
        Thromb Haemost. 2005; 93: 183-185
        • Ginsberg JS
        • Magier D
        • Mackinnon B
        • Gent M
        • Hirsh J
        Intermittent compression units for severe post-phlebitic syndrome: a randomized crossover study.
        CMAJ. 1999; 160: 1303-1306
        • O'Donnell MJ
        • McRae S
        • Kahn SR
        • et al.
        Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS). A randomized controlled trial.
        Thromb Haemost. 2008; 99: 623-629
        • Lyseng-Williamson KA
        • Perry CM
        Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
        Drugs. 2003; 63: 71-100
        • Shoab SS
        • Porter J
        • Scurr JH
        • Coleridge-Smith PD
        Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease—a prospective study.
        Eur J Vasc Endovasc Surg. 1999; 17: 313-318
        • de Jongste AB
        • Jonker JJ
        • Huisman MV
        • ten Cate JW
        • Azar AJ
        A double blind three center clinical trial on the short-term efficacy of 0-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome.
        Thromb Haemost. 1989; 62: 826-829
        • Monreal M
        • Callejas JM
        • Martorell A
        • et al.
        A prospective study of the long-term efficacy of two different venoactive drugs in patients with post-thrombotic syndrome.
        Phlebology. 1994; 9: 37-40
        • Campbell IA
        • Yeoh J
        • Medlicott S
        Duration of hospital stay in patients with pulmonary venous thromboembolism: a randomized comparison of unfractionated heparinversus low molecular weight heparin [Abstract].
        Thorax. 1998; 53: 254
        • Duroux P
        A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study.
        Thromb Haemost. 1991; 65: 251-256
        • Hull RD
        • Raskob GE
        • Pineo GF
        • et al.
        Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.
        N Engl J Med. 1992; 326: 975-982
        • Kirchmaier CM
        • Wolf H
        • Schäfer H
        • Ehlers B
        • Breddin HK
        • Certoparin-Study Group
        Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis.
        Int Angiol. 1998; 17: 135-145
        • Kuijer PM
        • Gallus AS
        • Cade J
        • et al.
        Randomized comparison of LMWH versus standard heparin in the initial treatment of pulmonary embolism [Abstract].
        Thromb Haemost. 1995; 73: 974
        • Meyer G
        • Brenot F
        • Pacouret G
        • et al.
        Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study.
        Thromb Haemost. 1995; 74: 1432-1435
        • Pérez de Llano LA
        • Baloira Villar A
        • Veres Racamonde A
        • Veiga F
        • Golpe Gómez R
        • Pajuelo Fernández F
        Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism [in Spanish].
        Arch Bronconeumol. 2003; 39: 341-345
        • Simonneau G
        • Sors H
        • Charbonnier B
        • et al.
        A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.
        N Engl J Med. 1997; 337: 663-669
        • The Columbus Investigators
        Low-molecular-weight heparin in the treatment of patients with.
        N Engl J Med. 1997; 337: 657-662
        • Théry C
        • Simonneau G
        • Meyer G
        • et al.
        Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study.
        Circulation. 1992; 85: 1380-1389
        • Quinlan DJ
        • McQuillan A
        • Eikelboom JW
        Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.
        Ann Intern Med. 2004; 140: 175-183
        • Otero R
        • Uresandi F
        • Jiménez D
        • et al.
        Home treatment in pulmonary embolism.
        Thromb Res. 2010; 126: e1-e5
        • Aujesky D
        • Roy PM
        • Verschuren F
        • et al.
        Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
        Lancet. 2011; 378: 41-48
        • Uresandi F
        • Otero R
        • Cayuela A
        • et al.
        [A clinical prediction rule for identifying short-term risk of adverse events in patients with pulmonary thromboembolism].
        Arch Bronconeumol. 2007; 43: 617-622
        • Wicki J
        • Perrier A
        • Perneger TV
        • Bounameaux H
        • Junod AF
        Predicting adverse outcome in patients with acute pulmonary embolism: a risk score.
        Thromb Haemost. 2000; 84: 548-552
        • Aujesky D
        • Obrosky DS
        • Stone RA
        • et al.
        Derivation and validation of a prognostic model for pulmonary embolism.
        Am J Respir Crit Care Med. 2005; 172: 1041-1046
        • Jiménez D
        • Yusen RD
        • Otero R
        • et al.
        Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy.
        Chest. 2007; 132: 24-30
        • Jiménez D
        • Aujesky D
        • Moores L
        • RIETE Investigators
        • et al.
        Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism.
        Arch Intern Med. 2010; 170: 1383-1389
        • Jakobsson C
        • Jiménez D
        • Gómez V
        • Zamarro C
        • Méan M
        • Aujesky D
        Validation of a clinical algorithm to identify low-risk patients with pulmonary embolism.
        J Thromb Haemost. 2010; 8: 1242-1247
        • Chan CM
        • Woods C
        • Shorr AF
        The validation and reproducibility of the pulmonary embolism severity index.
        J Thromb Haemost. 2010; 8: 1509-1514
        • Moores L
        • Aujesky D
        • Jiménez D
        • et al.
        Pulmonary Embolism Severity Index and troponin testing for the selection of low-risk patients with acute symptomatic pulmonary embolism.
        J Thromb Haemost. 2010; 8: 517-522
        • Fraga M
        • Taffé P
        • Méan M
        • et al.
        The inter-rater reliability of the Pulmonary Embolism Severity Index.
        Thromb Haemost. 2010; 104: 1258-1262
        • Squizzato A
        • Galli M
        • Dentali F
        • Ageno W
        Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review.
        Eur Respir J. 2009; 33: 1148-1155
        • Erkens PM
        • Gandara E
        • Wells P
        • et al.
        Safety of outpatient treatment in acute pulmonary embolism.
        J Thromb Haemost. 2010; 8: 2412-2417
        • Kovacs MJ
        • Hawel JD
        • Rekman JF
        • Lazo-Langner A
        Ambulatory management of pulmonary embolism: a pragmatic evaluation.
        J Thromb Haemost. 2010; 8: 2406-2411
        • Zondag W
        • Mos IC
        • Creemers-Schild D
        • Hestia Study Investigators
        • et al.
        Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study.
        J Thromb Haemost. 2011; 9: 1500-1507
        • Agterof MJ
        • Schutgens RE
        • Snijder RJ
        • et al.
        Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level.
        J Thromb Haemost. 2010; 8: 1235-1241
        • Baglin T
        Fifty per cent of patients with pulmonary embolism can be treated as outpatients.
        J Thromb Haemost. 2010; 8: 2404-2405
        • Dong B
        • Jirong Y
        • Wang Q
        Wu T Thrombolytic treatment for pulmonary embolism.
        Cochrane Database Syst Rev. 2006; : CD004437
        • Wood KE
        Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism.
        Chest. 2002; 121: 877-905
        • McIntyre KM
        • Sasahara AA
        Determinants of right ventricular function and hemodynamics after pulmonary embolism.
        Chest. 1974; 65: 534-543
        • Goldhaber SZ
        • Visani L
        • De Rosa M
        Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER).
        Lancet. 1999; 353: 1386-1389
        • Laporte S
        • Mismetti P
        • Décousus H
        • RIETE Investigators
        • et al.
        Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry.
        Circulation. 2008; 117: 1711-1716
        • Pollack CV
        • Schreiber D
        • Goldhaber SZ
        • et al.
        Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry).
        J Am Coll Cardiol. 2011; 57: 700-706
        • Sanchez O
        • Trinquart L
        • Caille V
        • et al.
        Prognostic factors for pulmonary embolism: the prep study, a prospective multicenter cohort study.
        Am J Respir Crit Care Med. 2010; 181: 168-173
        • Kucher N
        • Rossi E
        • De Rosa M
        • Goldhaber SZ
        Massive pulmonary embolism.
        Circulation. 2006; 113: 577-582
        • Torbicki A
        • Perrier A
        • Konstantinides S
        • ESC Committee for Practice Guidelines (CPG)
        • et al.
        Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).
        Eur Heart J. 2008; 29: 2276-2315
        • Douketis JD
        • Leeuwenkamp O
        • Grobara P
        • et al.
        The incidence and prognostic significance of elevated cardiac troponins in patients with submassive pulmonary embolism.
        J Thromb Haemost. 2005; 3: 508-513
        • Giannitsis E
        • Katus HA
        Risk stratification in pulmonary embolism based on biomarkers and echocardiography.
        Circulation. 2005; 112: 1520-1521
        • Konstantinides S
        • Geibel A
        • Olschewski M
        • et al.
        Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism.
        Circulation. 2002; 106: 1263-1268
        • Scridon T
        • Scridon C
        • Skali H
        • Alvarez A
        • Goldhaber SZ
        • Solomon SD
        Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism.
        Am J Cardiol. 2005; 96: 303-305
        • Becattini C
        • Vedovati MC
        • Agnelli G
        Prognostic value of troponins in acute pulmonary embolism: a meta-analysis.
        Circulation. 2007; 116: 427-433
        • Lankeit M
        • Friesen D
        • Aschoff J
        • et al.
        Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism.
        Eur Heart J. 2010; 31: 1836-1844
        • Lega JC
        • Lacasse Y
        • Lakhal L
        • Provencher S
        Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis.
        Thorax. 2009; 64: 869-875
        • Bova C
        • Pesavento R
        • Marchiori A
        • TELESIO Study Group
        • et al.
        Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with three months of follow-up.
        J Thromb Haemost. 2009; 7: 938-944
        • Stein PD
        • Matta F
        • Janjua M
        • Yaekoub AY
        • Jaweesh F
        • Alrifai A
        Outcome in stable patients with acute pulmonary embolism who had right ventricular enlargement and/or elevated levels of troponin I.
        Am J Cardiol. 2010; 106: 558-563
        • Sanchez O
        • Trinquart L
        • Colombet I
        • et al.
        Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review.
        Eur Heart J. 2008; 29: 1569-1577
        • Goldhaber SZ
        Echocardiography in the management of pulmonary embolism.
        Ann Intern Med. 2002; 136: 691-700
        • Schoepf UJ
        • Kucher N
        • Kipfmueller F
        • Quiroz R
        • Costello P
        • Goldhaber SZ
        Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism.
        Circulation. 2004; 110: 3276-3280
        • ten Wolde M
        • Söhne M
        • Quak E
        • Mac Gillavry MR
        • Büller HR
        Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism.
        Arch Intern Med. 2004; 164: 1685-1689
        • Frémont B
        • Pacouret G
        • Jacobi D
        • Puglisi R
        • Charbonnier B
        • de Labriolle A
        Prognostic value of echocardiographic right/left ventricular end-diastolic diameter ratio in patients with acute pulmonary embolism: results from a monocenter registry of 1,416 patients.
        Chest. 2008; 133: 358-362
        • Vanni S
        • Polidori G
        • Vergara R
        • et al.
        Prognostic value of ECG among patients with acute pulmonary embolism and normal blood pressure.
        Am J Med. 2009; 122: 257-264
        • Stein PD
        • Beemath A
        • Matta F
        • et al.
        Enlarged right ventricle without shock in acute pulmonary embolism: prognosis.
        Am J Med. 2008; 121: 34-42
        • Fiumara K
        • Kucher N
        • Fanikos J
        • Goldhaber SZ
        Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism.
        Am J Cardiol. 2006; 97: 127-129
        • Kanter DS
        • Mikkola KM
        • Patel SR
        • Parker JA
        • Goldhaber SZ
        Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors.
        Chest. 1997; 111: 1241-1245
      2. The urokinase pulmonary embolism trial. A national cooperative study.
        Circulation. 1973; 47: II1-II108
        • Dalla-Volta S
        • Palla A
        • Santolicandro A
        • et al.
        PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2.
        J Am Coll Cardiol. 1992; 20: 520-526
        • Dotter CT
        • Seamon AJ
        • Rosch J
        • et al.
        Streptokinase and heparin in the treatment of pulmonary embolism: a randomized comparison.
        Vasc Surg. 1979; 13: 42-52
        • PIOPED Investigators
        Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators.
        Chest. 1990; 97: 528-533
        • Jerjes-Sanchez C
        • Ramírez-Rivera A
        • de Lourdes García M, et al
        Streprokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial.
        J Thromb Thrombolysis. 1995; 2: 227-229
        • Ly B
        • Arnesen H
        • Eie H
        • Hol R
        A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism.
        Acta Med Scand. 1978; 203: 465-470
        • Marini C
        • Di Ricco G
        • Rossi G
        • Rindi M
        • Palla R
        • Giuntini C
        Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial.
        Respiration. 1988; 54: 162-173
        • Tibbutt DA
        • Davies JA
        • Anderson JA
        • et al.
        Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonay embolism.
        BMJ. 1974; 1: 343-347
      3. Urokinase pulmonary embolism trial. Phase I results: a cooperative study.
        JAMA. 1970; 214: 2163-2172
        • Becattini C
        • Agnelli G
        • Salvi A
        • TIPES Study Group
        • et al.
        Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism.
        Thromb Res. 2010; 125: e82-e86
        • Fasullo S
        • Scalzo S
        • Maringhini G
        • et al.
        Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin.
        Am J Med Sci. 2010; 341: 33-39
        • Goldhaber SZ
        • Haire WD
        • Feldstein ML
        • et al.
        Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion.
        Lancet. 1993; 341: 507-511
        • Konstantinides S
        • Geibel A
        • Heusel G
        • Heinrich F
        • Kasper W
        • Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators
        Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism.
        N Engl J Med. 2002; 347: 1143-1150
        • Levine M
        • Hirsh J
        • Weitz J
        • et al.
        A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.
        Chest. 1990; 98: 1473-1479
        • Agnelli G
        • Becattini C
        • Kirschstein T
        Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis.
        Arch Intern Med. 2002; 162: 2537-2541
        • Wan S
        • Quinlan DJ
        • Agnelli G
        • Eikelboom JW
        Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials.
        Circulation. 2004; 110: 744-749
      4. Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study.
        JAMA. 1974; 229: 1606-1613
        • Goldhaber SZ
        • Agnelli G
        • Levine MN
        • The Bolus Alteplase Pulmonary Embolism Group
        Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial.
        Chest. 1994; 106: 718-724
        • Goldhaber SZ
        • Kessler CM
        • Heit J
        • et al.
        Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.
        Lancet. 1988; 2: 293-298
        • Goldhaber SZ
        • Kessler CM
        • Heit JA
        • et al.
        Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial.
        J Am Coll Cardiol. 1992; 20: 24-30
        • Meneveau N
        • Schiele F
        • Vuillemenot A
        • et al.
        Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction.
        Eur Heart J. 1997; 18: 1141-1148
        • Meyer G
        • Sors H
        • Charbonnier B
        • The European Cooperative Study Group for Pulmonary Embolism
        • et al.
        Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial.
        J Am Coll Cardiol. 1992; 19: 239-245
        • Sors H
        • Pacouret G
        • Azarian R
        • Meyer G
        • Charbonnier B
        • Simonneau G
        Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial.
        Chest. 1994; 106: 712-717
        • Tebbe U
        • Bramlage P
        • Graf A
        • et al.
        Desmoteplase in acute massive pulmonary thromboembolism.
        Thromb Haemost. 2009; 101: 557-562
        • Tebbe U
        • Graf A
        • Kamke W
        • et al.
        Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism.
        Am Heart J. 1999; 138: 39-44
        • Wang C
        • Zhai Z
        • Yang Y
        • China Venous Thromboembolism (VTE) Study Group
        • et al.
        Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial.
        Chest. 2010; 137: 254-262
        • Wang C
        • Zhai Z
        • Yang Y
        • China Venous Thromboembolism Study Group
        • et al.
        Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial.
        Respir Res. 2009; 10: 128
        • Meneveau N
        • Schiele F
        • Metz D
        • et al.
        Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up.
        J Am Coll Cardiol. 1998; 31: 1057-1063
        • Verstraete M
        • Miller GAH
        • Bounameaux H
        • et al.
        Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism.
        Circulation. 1988; 77: 353-360
        • de Gregorio M
        • Gimeno M
        • Alfonso R
        • et al.
        [Mechanical fragmentation and intrapulmonary fibrinolysis in the treatment of massive pulmonary embolism hemodynamic repercussions].
        Arch Bronconeumol. 2001; 37: 58-64
        • Fava M
        • Loyola S
        • Flores P
        • Huete I
        Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism.
        J Vasc Interv Radiol. 1997; 8: 261-266
        • Schmitz-Rode T
        • Janssens U
        • Duda SH
        • Erley CM
        • Günther RW
        Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter.
        J Am Coll Cardiol. 2000; 36: 375-380
        • Schmitz-Rode T
        • Janssens U
        • Schild HH
        • Basche S
        • Hanrath P
        • Günther RW
        Fragmentation of massive pulmonary embolism using a pigtail rotation catheter.
        Chest. 1998; 114: 1427-1436
        • Kucher N
        Catheter embolectomy for acute pulmonary embolism.
        Chest. 2007; 132: 657-663
        • Kuo WT
        • Gould MK
        • Louie JD
        • Rosenberg JK
        • Sze DY
        • Hofmann LV
        Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques.
        J Vasc Interv Radiol. 2009; 20: 1431-1440
        • Margheri M
        • Vittori G
        • Vecchio S
        • et al.
        Early and long-term clinical results of AngioJet rheolytic thrombectomy in patients with acute pulmonary embolism.
        Am J Cardiol. 2008; 101: 252-258
        • Zhou WZ
        • Shi HB
        • Yang ZQ
        • et al.
        Value of percutanous catheter fragmentation in the management of massive pulmonary embolism.
        Chin Med J (Engl). 2009; 122: 1723-1727
        • Leacche M
        • Unic D
        • Goldhaber SZ
        • et al.
        Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach.
        J Thorac Cardiovasc Surg. 2005; 129: 1018-1023
        • Meneveau N
        • Séronde MF
        • Blonde MC
        • et al.
        Management of unsuccessful thrombolysis in acute massive pulmonary embolism.
        Chest. 2006; 129: 1043-1050
        • Sukhija R
        • Aronow WS
        • Lee J
        • et al.
        Association of right ventricular dysfunction with in-hospital mortality in patients with acute pulmonary embolism and reduction in mortality in patients with right ventricular dysfunction by pulmonary embolectomy.
        Am J Cardiol. 2005; 95: 695-696
        • Fukuda I
        • Taniguchi S
        • Fukui K
        • Minakawa M
        • Daitoku K
        • Suzuki Y
        Improved outcome of surgical pulmonary embolectomy by aggressive intervention for critically ill patients.
        Ann Thorac Surg. 2011; 91: 728-732
        • Beckman JA
        • Dunn K
        • Sasahara AA
        • Goldhaber SZ
        Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism.
        Thromb Haemost. 2003; 89: 953-958
        • Kucher N
        • Quiroz R
        • McKean S
        • Sasahara AA
        • Goldhaber SZ
        Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism.
        Vasc Med. 2005; 10: 251-256
        • Schulman S
        • Kearon C
        • Kakkar AK
        • RE-COVER Study Group
        • et al.
        Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
        N Engl J Med. 2009; 361: 2342-2352
        • Gosselin MV
        • Rubin GD
        • Leung AN
        • Huang J
        • Rizk NW
        Unsuspected pulmonary embolism: prospective detection on routine helical CT scans.
        Radiology. 1998; 208: 209-215
        • O'Connell CL
        • Boswell WD
        • Duddalwar V
        • et al.
        Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance.
        J Clin Oncol. 2006; 24: 4928-4932
        • Sebastian AJ
        • Paddon AJ
        Clinically unsuspected pulmonary embolism—an important secondary finding in oncology CT.
        Clin Radiol. 2006; 61: 81-85
        • Storto ML
        • Di Credico A
        • Guido F
        • Larici AR
        • Bonomo L
        Incidental detection of pulmonary emboli on routine MDCT of the chest.
        AJR Am J Roentgenol. 2005; 184: 264-267
        • Douma RA
        • Kok MG
        • Verberne LM
        • Kamphuisen PW
        • Büller HR
        Incidental venous thromboembolism in cancer patients: prevalence and consequence.
        Thromb Res. 2010; 125: e306-e309
        • Farrell C
        • Jones M
        • Girvin F
        • Ritchie G
        • Murchison JT
        Unsuspected pulmonary embolism identified using multidetector computed tomography in hospital outpatients.
        Clin Radiol. 2010; 65: 1-5
        • Hui GC
        • Legasto A
        • Wittram C
        The prevalence of symptomatic and coincidental pulmonary embolism on computed tomography.
        J Comput Assist Tomogr. 2008; 32: 783-787
        • den Exter PL
        • Hooijer J
        • Dekkers OM
        • Huisman MV
        Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients.
        J Clin Oncol. 2011; 29: 2405-2409
        • Dentali F
        • Ageno W
        • Pierfranceschi MG
        • et al.
        Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer.
        J Thromb Haemost. 2011; 9: 1081-1083
        • O'Connell C
        • Razavi P
        • Ghalichi M
        • et al.
        Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning.
        J Thromb Haemost. 2011; 9: 305-311
        • Becattini C
        • Agnelli G
        • Pesavento R
        • et al.
        Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism.
        Chest. 2006; 130: 172-175
        • Pengo V
        • Lensing AWA
        • Prins MH
        • Thromboembolic Pulmonary Hypertension Study Group
        • et al.
        Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism.
        N Engl J Med. 2004; 350: 2257-2264
        • Ribeiro A
        • Lindmarker P
        • Johnsson H
        • Juhlin-Dannfelt A
        • Jorfeldt L
        Pulmonary embolism: one-year follow-up with echocardiography Doppler and five-year survival analysis.
        Circulation. 1999; 99: 1325-1330
        • Dentali F
        • Donadini M
        • Gianni M
        • et al.
        Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism.
        Thromb Res. 2009; 124: 256-258
        • Kline JA
        • Steuerwald MT
        • Marchick MR
        • Hernandez-Nino J
        • Rose GA
        Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure.
        Chest. 2009; 136: 1202-1210
        • Hoeper MM
        • Mayer E
        • Simonneau G
        • Rubin LJ
        Chronic thromboembolic pulmonary hypertension.
        Circulation. 2006; 113: 2011-2020
        • Jamieson SW
        • Kapelanski DP
        • Sakakibara N
        • et al.
        Pulmonary endarterectomy: experience and lessons learned in 1,500 cases.
        Ann Thorac Surg. 2003; 76: 1457
        • Fedullo PF
        • Auger WR
        • Kerr KM
        • Rubin LJ
        Chronic thromboembolic pulmonary hypertension.
        N Engl J Med. 2001; 345: 1465-1472
        • Bernard J
        • Yi ES
        Pulmonary thromboendarterectomy: a clinicopathologic study of 200 consecutive pulmonary thromboendarterectomy cases in one institution.
        Hum Pathol. 2007; 38: 871-877
        • Thistlethwaite PA
        • Kaneko K
        • Madani MM
        • Jamieson SW
        Technique and outcomes of pulmonary endarterectomy surgery.
        Ann Thorac Cardiovasc Surg. 2008; 14: 274-282
        • Doyle RL
        • McCrory D
        • Channick RN
        • Simonneau G
        • Conte J
        • American College of Chest Physicians
        Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
        Chest. 2004; 126: 63S-71S
        • Mehta S
        • Helmersen D
        • Provencher S
        • for the Canadian Thoracic Society Pulmonary Vascular Disease - CTEPH CPG Development Committee
        • the Canadian Thoracic Society Canadian Respiratory Guidelines Committee
        • et al.
        Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: A clinical practice guideline.
        Can Respir J. 2010; 17: 301-334
        • Mayer E
        • Jenkins D
        • Lindner J
        • et al.
        Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry.
        J Thorac Cardiovasc Surg. 2011; 141: 702-710
        • Pepke-Zaba J
        • Delcroix M
        • Lang I
        • et al.
        Chronic thromboembolic pulmonary hypertension (CTEPH). Results from an international prospective registry.
        Circulation. 1973-1981; 124
        • Feinstein JA
        • Goldhaber SZ
        • Lock JE
        • Ferndandes SM
        • Landzberg MJ
        Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension.
        Circulation. 2001; 103: 10-13
        • Bresser P
        • Pepke-Zaba J
        • Jaïs X
        • Humbert M
        • Hoeper MM
        Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm.
        Proc Am Thorac Soc. 2006; 3: 594-600
        • Becattini C
        • Manina G
        • Busti C
        • Gennarini S
        • Agnelli G
        Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis.
        Thromb Res. 2010; 126: e51-e56
        • Decousus H
        • Epinat M
        • Guillot K
        • Quenet S
        • Boissier C
        • Tardy B
        Superficial vein thrombosis: risk factors, diagnosis, and treatment.
        Curr Opin Pulm Med. 2003; 9: 393-397
        • Wichers IM
        • Di Nisio M
        • Büller HR
        • Middeldorp S
        Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review.
        Haematologica. 2005; 90: 672-677
        • Quenet S
        • Laporte S
        • Décousus H
        • Leizorovicz A
        • Epinat M
        • Mismetti P
        • STENOX Group
        Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis.
        J Vasc Surg. 2003; 38: 944-949
        • Decousus H
        • Quéré I
        • Presles E
        • POST (Prospective Observational Superficial Thrombophlebitis) Study Group
        • et al.
        Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study.
        Ann Intern Med. 2010; 152: 218-224
        • Di Nisio M
        • Wichers IM
        • Middeldorp S
        Treatment for superficial thrombophlebitis of the leg.
        Cochrane Database Syst Rev. 2007; : CD004982
        • Superficial Thrombophlebitis Treated By Enoxaparin Study Group
        A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis.
        Arch Intern Med. 2003; 163: 1657-1663
        • Titon JP
        • Auger D
        • Grange P
        • et al.
        [Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with a non-steroidal anti-inflammatory agent].
        Ann Cardiol Angeiol (Paris). 1994; 43: 160-166
        • Prandoni P
        • Tormene D
        • Pesavento R
        • Vesalio Investigators Group
        High vs. low doses of low-molecular-weight heparin for the treatment of superficial vein thrombosis of the legs: a double-blind, randomized trial.
        J Thromb Haemost. 2005; 3: 1152-1157
        • Marchiori A
        • Verlato F
        • Sabbion P
        • et al.
        High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study.
        Haematologica. 2002; 87: 523-527
        • Belcaro G
        • Nicolaides AN
        • Errichi BM
        • et al.
        Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study.
        Angiology. 1999; 50: 523-529
        • Andreozzi GM
        • Signorelli S
        • Di Pino L
        • et al.
        Tolerability and clinical efficacy of desmin in the treatment of superficial thrombovaricophlebitis.
        Angiology. 1996; 47: 887-894
        • Decousus H
        • Prandoni P
        • Mismetti P
        • CALISTO Study Group
        • et al.
        Fondaparinux for the treatment of superficial-vein thrombosis in the legs.
        N Engl J Med. 2010; 363: 1222-1232
      5. Blondon M, Righini M, Bounameaux H, et al. Fondaparinux for isolated superficial-vein thrombosis of the legs: a cost-effectiveness analysis. Chest, In press. 10.1378/chest.11-0625

        • Lozano FS
        • Almazan A
        Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: a prospective study.
        Vasc Endovascular Surg. 2003; 37: 415-420
        • Sullivan V
        • Denk PM
        • Sonnad SS
        • Eagleton MJ
        • Wakefield TW
        Ligation versus anticoagulation: treatment of above-knee superficial thrombophlebitis not involving the deep venous system.
        J Am Coll Surg. 2001; 193: 556-562
        • Flinterman LE
        • Van Der Meer FJ
        • Rosendaal FR
        • Doggen CJ
        Current perspective of venous thrombosis in the upper extremity.
        J Thromb Haemost. 2008; 6: 1262-1266
        • Lechner D
        • Wiener C
        • Weltermann A
        • Eischer L
        • Eichinger S
        • Kyrle PA
        Comparison between idiopathic deep vein thrombosis of the upper and lower extremity regarding risk factors and recurrence.
        J Thromb Haemost. 2008; 6: 1269-1274
        • Spencer FA
        • Emery C
        • Lessard D
        • Goldberg RJ
        • Worcester Venous Thromboembolism Study
        Upper extremity deep vein thrombosis: a community-based perspective.
        Am J Med. 2007; 120: 678-684
        • Owens CA
        • Bui JT
        • Knuttinen MG
        • Gaba RC
        • Carrillo TC
        Pulmonary embolism from upper extremity deep vein thrombosis and the role of superior vena cava filters: a review of the literature.
        J Vasc Interv Radiol. 2010; 21: 779-787
        • Mai C
        • Hunt D
        Upper-extremity deep venous thrombosis: a review.
        Am J Med. 2011; 124: 402-407
        • Becker DM
        • Philbrick JT
        • Walker IV, FB
        Axillary and subclavian venous thrombosis. Prognosis and treatment.
        Arch Intern Med. 1991; 151: 1934-1943
        • Joffe HV
        • Kucher N
        • Tapson VF
        • Goldhaber SZ
        • Deep Vein Thrombosis (DVT) FREE Steering Committee
        Upper-extremity deep vein thrombosis: a prospective registry of 592 patients.
        Circulation. 2004; 110: 1605-1611
        • Prandoni P
        • Polistena P
        • Bernardi E
        • et al.
        Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications.
        Arch Intern Med. 1997; 157: 57-62
        • Kucher N
        Clinical practice. Deep-vein thrombosis of the upper extremities.
        N Engl J Med. 2011; 364: 861-869
        • Prandoni P
        • Bernardi E
        • Marchiori A
        • et al.
        The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study.
        BMJ. 2004; 329: 484-485
        • Elman EE
        • Kahn SR
        The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review.
        Thromb Res. 2006; 117: 609-614
        • Baskin JL
        • Pui CH
        • Reiss U
        • et al.
        Management of occlusion and thrombosis associated with long-term indwelling central venous catheters.
        Lancet. 2009; 374: 159-169
        • Saber W
        • Moua T
        • Williams EC
        • et al.
        Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies.
        J Thromb Haemost. 2011; 9: 312-319
        • Savage KJ
        • Wells PS
        • Schulz V
        • et al.
        Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity.
        Thromb Haemost. 1999; 82: 1008-1010
        • Karabay O
        • Yetkin U
        • Onol H
        Upper extremity deep vein thrombosis: clinical and treatment characteristics.
        J Int Med Res. 2004; 32: 429-435
        • Kovacs MJ
        • Kahn SR
        • Rodger M
        • et al.
        A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study).
        J Thromb Haemost. 2007; 5: 1650-1653
        • AbuRahma AF
        • Short YS
        • White III, JF
        • Boland JP
        Treatment alternatives for axillary-subclavian vein thrombosis: long-term follow-up.
        Cardiovasc Surg. 1996; 4: 783-787
        • Horne III, MK
        • Mayo DJ
        • Cannon III, RO
        • Chen CC
        • Shawker TH
        • Chang R
        Intraclot recombinant tissue plasminogen activator in the treatment of deep venous thrombosis of the lower and upper extremities.
        Am J Med. 2000; 108: 251-255
        • Lee JT
        • Karwowski JK
        • Harris EJ
        • Haukoos JS
        • Olcott IV, C
        Long-term thrombotic recurrence after nonoperative management of Paget-Schroetter syndrome.
        J Vasc Surg. 2006; 43: 1236-1243
        • Lokanathan R
        • Salvian AJ
        • Chen JC
        • Morris C
        • Taylor DC
        • Hsiang YN
        Outcome after thrombolysis and selective thoracic outlet decompression for primary axillary vein thrombosis.
        J Vasc Surg. 2001; 33: 783-788
        • Pegis JD
        • Papon X
        • Pasco A
        • Regnard O
        • Abraham P
        • Enon B
        [In situ thrombolysis in the treatment of venous thrombosis of effort in the arm [in French].
        J Mal Vasc. 1997; 22: 187-192
        • Petrakis IE
        • Katsamouris A
        • Kafassis E
        • D'Anna M
        • Sciacca V, V
        Two Different Therapeutic Modalities in the Treatment of the Upper Extremity Deep Vein Thrombosis: Preliminary Investigation With 20 Case Reports.
        Int J Angiol. 2000; 9: 46-50
        • Sabeti S
        • Schillinger M
        • Mlekusch W
        • Haumer M
        • Ahmadi R
        • Minar E
        Treatment of subclavian-axillary vein thrombosis: long-term outcome of anticoagulation versus systemic thrombolysis.
        Thromb Res. 2002; 108: 279-285
        • Schindler J
        • Bona RD
        • Chen HH
        • et al.
        Regional thrombolysis with urokinase for central venous catheter-related thrombosis in patients undergoing high-dose chemotherapy with autologous blood stem cell rescue.
        Clin Appl Thromb Hemost. 1999; 5: 25-29
        • Kahn SR
        • Elman EA
        • Bornais C
        • Blostein M
        • Wells PS
        Post-thrombotic syndrome, functional disability and quality of life after upper extremity deep venous thrombosis in adults.
        Thromb Haemost. 2005; 93: 499-502
        • Machleder HI
        Evaluation of a new treatment strategy for Paget-Schroetter syndrome: spontaneous thrombosis of the axillary-subclavian vein.
        J Vasc Surg. 1993; 17 (discussion 316-317.): 305-315
        • Schneider DB
        • Dimuzio PJ
        • Martin ND
        • et al.
        Combination treatment of venous thoracic outlet syndrome: open surgical decompression and intraoperative angioplasty.
        J Vasc Surg. 2004; 40: 599-603